Equities

Nuformix PLC

Nuformix PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.175
  • Today's Change-0.005 / -2.78%
  • Shares traded3.26m
  • 1 Year change-20.45%
  • Beta1.2146
Data delayed at least 20 minutes, as of Jul 05 2024 14:28 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001 is pursuing licensing opportunities. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-341.86k
  • Incorporated2015
  • Employees2.00
  • Location
    Nuformix PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
  • Phone+44 122 362 7222
  • Websitehttps://nuformix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Procyon Corp3.73m-302.72k1.33m17.00--0.8022--0.3567-0.0478-0.04780.58910.27741.391.949.60280,817.70-10.813.52-13.694.2378.0173.30-7.782.522.22--0.00---3.223.1170.44--30.98--
DH Enchantment Inc1.46k-85.91k1.36m3.00------933.56-0.0001-0.00010.00-0.00110.0971--46.75623.33-571.54------132.62---5,885.03--0.0021-8.29-----97.25--12.89------
SOHM Inc-78.06bn-78.06bn1.37m--------------------------------------------------------------
Link Reservations Inc0.00-375.41k1.40m0.00---------46.51-46.510.00-13.990.00-------246.84-----------------2.43---------22.69------
Nuformix PLC0.00-341.86k1.43m2.00--0.3495-----0.0005-0.00050.000.0050.00-------7.72---8.21--------------0.00--------------
Nexien Biopharma Inc0.00-192.18k1.44m0.00---------0.0038-0.00380.00-0.00480.00-------679.40-860.53---1,653.53-----------1.77--------42.22------
Hydration Pharmaceuticals Co Ltd7.87m-6.35m1.45m--------0.1839-0.0618-0.06180.0765-0.0021.181.616.60---94.86-79.98-143.75-111.5753.7048.73-80.69-99.531.37-21.481.10--10.3419.2723.61------
AgriFORCE Growing Systems Ltd12.71k-10.41m1.46m7.00--0.1811--114.67-10.78-10.780.00390.3960.0009--0.4432,325.71-74.39-78.95-100.77-109.8616.58---81,946.25-243,182.500.8186-1.300.1913------8.85--48.61--
Pharmesis International Ltd.4.91m-533.84k1.49m----0.2353--0.3025-0.0341-0.03410.32140.34420.49661.884.96---5.34-6.47-9.13-10.2145.6148.72-10.75-13.390.5848-4.520.2337---9.40-6.64-39.27---32.66--
CanaQuest Medical Corp0.00-630.21k1.49m-----------0.0514-0.05140.00-0.0370.00-------1,084.38--------------------------57.42------
Intellipharmaceutics International Inc706.33k-2.48m1.52m33.00------2.15-0.1308-0.13080.0373-0.53070.6027--3.37---211.39-132.15-----88.96---350.72-499.37---19.36-------58.7543.78------
Radient Technologies Inc1.80m-6.47m1.55m33.00------0.859-0.0216-0.02160.006-0.02780.11081.566.00---39.76-67.36---118.27-3.911.66-359.00-534.110.0251-3.58----45.4965.3069.41--200.33--
Ortin Laboratories Ltd197.38k-751.66k1.56m----5.91--7.91-9.89-9.892.593.470.1522.810.8146---57.87-3.46-85.68-8.85-75.9523.25-380.81-3.673.09-14.040.3896---64.93-58.32-8,490.81------
Data as of Jul 05 2024. Currency figures normalised to Nuformix PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.